{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '9.2.', 'Data Quality Control and Quality Assurance', '72', '9.2.1.', 'Data Handling', '72', '9.2.2.', 'Study Monitoring', '72', '9.2.3.', 'Audits and Inspections', '73', '9.3.', 'Publication Policy', '73', '9.4.', 'Dissemination of Clinical Study Data', '73', '10.', 'LIST OF REFERENCES', '74', '11.', 'APPENDICES', '76', '11.1.', 'Pharmacokinetic Assessment Time Points', '76', '11.2.', 'Perioperative Schedule of Assessments', '78', '11.2.1.', 'Definitions of Minor and Major Surgery', '78', '11.2.2.', 'Perioperative Assessments of Safety and Hemostatic Efficacy in Patients', 'Undergoing Operative Procedures', '78', '11.3.', 'International Society on Thrombosis and Hemostasis Guideline for', 'Assessment of Treatment Response', '80', '11.4.', 'Bleed Severity Definitions', '80', '11.5.', 'Country-Specific Requirements', '80', '11.6.', 'Protocol Amendment History', '81', '11.6.1.', 'Amended Protocol 01', '81', 'Property of the Sanofi Group - strictly confidential', '21', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'LIST OF TABLES', 'Table 1:', 'Schedule of Assessments', '11', 'Table 2:', 'Bleeding Episode Assessments - Unscheduled Visit', '16', 'Table 3:', 'Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed', 'Isolated Elevations of ALT and/or AST >3x ULN, with No Alternative', 'Cause Identified', '44', 'Table 4:', 'Bleed Management Dosing Guidelines by Specific Product', '49', 'Table 5:', 'Clinical Laboratory Assessments', '58', 'Table 6:', 'Hepatic Assessments in Patients who Experience LFT Elevations', '60', 'Table 7:', 'Pharmacokinetic Time Points for All Fitusiran Arm Patients', '76', 'Table 8:', 'Pharmacokinetic (Fitusiran Arm), AT, and TG Time Points for East Asian', 'Patients at East Asian Sites', '77', 'Table 9:', 'Urine Pharmacokinetic Time Points for East Asian Patients in the Fitusiran', 'Arm from East Asian sites', '77', 'Table 10: Perioperative Schedule of Assessments in Patients Undergoing Operative', 'Procedures', '79', 'Table 11:', 'Assessment of Treatment of Acute Joint/Muscle Bleeding Episodes', '80', 'Table 12', 'Bleed Severity Definitions', '80', 'LIST OF FIGURES', 'Figure 1:', 'Study Design', '37', 'Property of the Sanofi Group - strictly confidential', '22', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', 'Abbreviation or Specialist Term', 'Explanation', 'ABR', 'Annualized bleeding rate', 'ADA', 'Antidrug antibody', 'AE', 'Adverse event', 'ALP', 'Alkaline phosphatase', 'ALT', 'Alanine aminotransferase', 'ANCOVA', 'Analysis of covariance', 'aPCC', 'Activated prothrombin complex concentrates', 'AST', 'Aspartate aminotransferase', 'AT', 'Antithrombin', 'AUC', 'Area under the concentration-time curve', 'BPA', 'Bypassing agent', 'BU', 'Bethesda units', 'BUN', 'Blood urea nitrogen', 'CBC', 'Complete blood count', 'CFR', 'Code of Federal Regulation', 'CI', 'Confidence interval', 'CL/F', 'Apparent clearance', 'Cmax', 'Maximum plasma concentration', 'CRF', 'Case report form', 'CRP', 'C-reactive protein', 'CT', 'Computed tomography', 'CVST', 'Cerebral venous sinus thrombosis', 'CYP P450', 'Cytochrome P450', 'DMC', 'Data Monitoring Committee', 'DTP', 'Duties and taxes paid', 'ECG', 'Electrocardiogram', 'eCRF', 'Electronic case report form', 'eDiary', 'Electronic diary', 'EE', 'Efficacy-evaluable', 'EQ-5D', 'EuroQol-5 dimension', 'Property of the Sanofi Group - strictly confidential', '23', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}